IP Library Patent Application 12752796
Patent Application
App. No. 12/752,796

Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/752,796
Abstract

The present invention relates to modifying rapid immunochromatographic (“ICT”) tests for the detection of characteristic carbohydrate antigens of bacteria that are known to be causative of otitis media and respiratory diseases in children under the age of approximately 12 years. Children of this age group are also prone to nasopharyngeal colonization with the same bacteria, and urine samples taken from colonized, but otherwise healthy, children were shown to exhibit an unduly high incidence of test results that were false positive for the presence of disease. The test modifications, which maintain the test sensitivity unchanged and the test specificity at a value above 90% were developed to insure that healthy, albeit colonized, children were not medicated for disease the bacteria are known to cause. The modifications involve either (1) reducing the total amount of antibodies to the carbohydrate antigen employed in each test, (2) adding at least one fixed “scrub” line located just prior to the capture line in the sample flow path to the preprepared ICT test strip to “scrub” out an identical amount of target antigen from all bodily fluid test samples obtained from both colonized but otherwise healthy children and diseased children, or (3) combinations of (1) and (2).

Claims (13)

1 . In a bioassay for the detection in bodily fluids of teenage and adult humans of an antigen that is characteristic of a kind of bacteria causative of human ear and respiratory tract infections, which kind of bacteria also frequently colonizes the nasopharynx areas of children up to the age of about 12 years without infecting them,

the improvement in said bioassay for detection of said antigen in bodily fluid samples from said children up to the age of about 12 years which at least substantially reduces the incidence of false positive results stemming from nasopharyngeal colonization of otherwise healthy children, while maintaining the sensitivity of said bioassay to the presence of said antigen stemming from an infection and also maintaining the specificity of said bioassay at not less than 90%,

which improvement consists in reducing the total amount of antibodies to said antigen that are employed in each bioassay to a total amount less than that utilized in the otherwise identical bioassay employed in testing bodily fluids of teenage and adult humans, wherein the amount of reduction of total antibodies needed to obtain the stated results has been determined empirically in bioassay tests, wherein the total amount of antibodies present per test are varied, and the tests representing each variation are run identically on samples of bodily fluids taken from each of (1) otherwise healthy children known to have nasopharyngeal colonization by the bacteria of which the antigen is characteristic and (2) children known to have an ear or pneumococcal infection caused by the kind of bacteria of which the antigen is characteristic.

2 . The improvement according to claim 1 wherein the antigen is characteristic of a kind of bacteria selected from among Streptococcus pneumoniae, nontypable Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus.

3 . The improvement according to claim 2 wherein the antigen is a carbohydrate antigen characteristic of one of these bacteria.

4 . The improvement according to claim 3 wherein the antigen is the polysaccharide antigen common to all serotypes of Streptococcus pneumoniae, and the kind of bacteria is Streptococcus pneumoniae.

5 . The improvement according to claim 1 wherein the bioassay is an immunochromatographic assay.

6 . The improvement according to claim 5 where the antibodies in each test are in part conjugated to a tag, in movable form, and in part immovably fixed on a capture line where tagged antibody-antigen-fixed antibody “sandwiches” form and mass at the conclusion of the bioassay.

7 . The improvement according to claim 6 wherein the antibodies are antibodies to the polysaccharide antigen common to all serotypes of Streptococcus pneumoniae and the kind of bacteria is Streptococcus pneumoniae.

8 . The improvement according to claim 6 wherein the amount of reduction of total antibodies needed to achieve the stated results has been empirically determined to be that attained (1) by conjugating a part of the antibodies to colloidal gold and making a conjugate solution having an optical density of 1.5 and (2) the concentration of antibody immovably fixed to the capture line is placed there from a solution containing 0.3 mg./ml. of antibody delivered at a rate of 0.5 ml. per 6 mm. of substrate by the delivery tip of a precision pump.

9 . In an immunochromatographic (“ICT”) bioassay for the detection in bodily fluids of teenage and adult humans of an antigen that is characteristic of a kind of bacteria causative of human ear and respiratory tract infections, which kind of bacteria also frequently colonizes the nasopharynx areas of children up to the age of about 12 years without infecting them,

the improvement in said biassay for detection of said antigen in bodily fluid samples from said children up to the age of about 12 years which at least substantially reduces the incidence of false positive results stemming from nasopharyngeal colonization of otherwise healthy children, while maintaining the sensitivity of said bioassay to the presence in bodily fluids of said antigen stemming from an infection and also maintaining the specificity of said bioassay at not less than 90%,

which improvement consists in adding at least one immovable “scrub” line located just prior to the capture line in the sample flow path of the ICT test strip to remove excess antigen by “scrubbing” out an identical portion thereof from samples of bodily fluid of each of (a) uninfected children who are colonized nasopharyngeally by the bacteria of which the antigen is characteristic and (b) persons who are infected by the same bacteria, wherein the number of capture lines, the concentration of antibody deposited on each capture line and the extent to which the concentration of antibodies otherwise employed in the test is modified, if at all, in order to obtain the stated results, have been determined empirically in bioassay tests wherein the number of “scrub” lines and the concentration of antibody on each “scrub” line and the concentration of antibodies otherwise present per test are varied and tests representing each variation are run identically on samples of bodily fluids taken from each of (1) otherwise healthy children known to have nasopharyngeal colonization by the bacteria of which the antigen is characteristic and (2) children known to have an ear or pneumococcal infection caused by the kind of bacteria of which the antigen is characteristic.

Assignments (9)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2013
From: PIASIO, ROGER N.; WAREING, MADELINE
To: BINAX, INC.
Reel/Frame 030522/0981 →
CHANGE OF NAME Recorded May 31, 2013
From: BINAX, INC.
To: ALERE SCARBOROUGH, INC.
Reel/Frame 030523/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2011
From: PIASIO, ROGER N.; WAREING, MADELINE
To: BINAX, INC.
Reel/Frame 026838/0304 →
CHANGE OF NAME Recorded Aug 31, 2011
From: BINAX, INC.
To: ALERE SCARBOROUGH, INC.
Reel/Frame 026838/0452 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →